Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR1 | P25024 | 20/20 | 0.88 |
| ▸ | CXCR2 | P25025 | 20/20 | 0.88 |
| ▸ | CCR7 | P32248 | 4/20 | 0.88 |
| ▸ | CCR6 | P51684 | 3/20 | 0.71 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.71 |
| ▸ | CCR4 | P51679 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12262746 | 0.94 | CXCR2 (1.00) | CXCR1CXCR2CCR7CCR6CXCR3 | |
| SCHEMBL12262779 | 0.92 | CXCR1 (0.93) | CXCR1CXCR2CCR7CCR6CXCR3 | |
| SCHEMBL14894600 | 0.90 | CXCR2 (1.00) | CXCR1CXCR2CCR7CCR6CXCR3 | |
| SCHEMBL14895104 | 0.90 | CXCR2 (1.00) | CXCR1CXCR2CCR7CCR6CXCR3 | |
| SCHEMBL21297010 | 0.90 | CXCR2 (1.00) | CXCR1CXCR2CCR7CCR6CXCR3 | |
| SCHEMBL14894938 | 0.87 | CXCR1 (0.84) | CXCR1CXCR2CCR7CCR6CXCR3 | |
| SCHEMBL14895442 | 0.84 | CXCR1 (1.00) | CXCR1CXCR2CCR7CCR6CXCR3 | |
| SCHEMBL14895441 | 0.84 | CXCR1 (1.00) | CXCR1CXCR2CCR7CCR6CXCR3 | |
| SCHEMBL14895297 | 0.84 | CXCR1 (1.00) | CXCR1CXCR2CCR7CCR6CXCR3 | |
| SCHEMBL14894973 | 0.84 | CXCR1 (1.00) | CXCR1CXCR2CCR7CCR6CXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10660909-B2 | Method for treating cancer using chemokine antagonists | SYNTRIX BIOSYSTEMS INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-20180177808-A1 | METHOD FOR TREATING CANCER USING CHEMOKINE ANTAGONISTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-06-28 | — | — | US | disclosed |
| US-20180177808-A1 | METHOD FOR TREATING CANCER USING CHEMOKINE ANTAGONISTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180177808-A1 | METHOD FOR TREATING CANCER USING CHEMOKINE ANTAGONISTS | CXCR1, CXCR2, CXCR5 | CXCR1 1/4885CXCR2 2/4885CCR7 9/4885 |
| US-10660909-B2 | Method for treating cancer using chemokine antagonists | CXCR1, CXCR2, CXCR5 | CXCR1 1/4885CXCR2 2/4885CCR7 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.